Graft Versus Host Disease clinical trials at UCSD
4 in progress, 1 open to eligible people
Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
open to eligible people ages 12 years and up
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
La Jolla, California and other locations
Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Sorry, in progress, not accepting new patients
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
La Jolla, California and other locations
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Sorry, in progress, not accepting new patients
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.
La Jolla, California
Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Sorry, accepting new patients by invitation only
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
La Jolla, California and other locations
Our lead scientists for Graft Versus Host Disease research studies include Dimitrios Tzachanis, MD PhD Divya Koura, MD.
Last updated: